Sato Pharmaceutical Inc. is recalling 384,216 units of Zentrip, WAL-DRAM 2, and other motion sickness medications containing meclizine hydrochloride. These products are being recalled because they were found to be subpotent, meaning they may not contain the full labeled amount of active medication. The recall affects various formats including tablets and oral strips distributed nationwide within the United States, Guam, and Saipan.
Subpotent medication may not provide the intended level of treatment for motion sickness symptoms, such as nausea, dizziness, and vomiting, potentially leading to ineffective symptom management for the consumer.
Contact healthcare provider and return product for refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.